tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alnylam price target raised to $260 from $210 at Evercore ISI

Evercore ISI analyst Liisa Bayko raised the firm’s price target on Alnylam to $260 from $210 and keeps an Outperform rating on the shares after the company’s HELIOS-B data “beat wavering expectations.” The firm is moving its view of the odds of success for vutrisiran in ATTR-CM patients to 80% from 70% and notes that its “fully loaded” target assuming U.S. approval in Q3 of 2025 would be $300 per share.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1